Aradigm/Novo Nordisk Inhaled Insulin Manufacturing Issues Appear Resolved
This article was originally published in The Pink Sheet Daily
Concerns over cosmetic blemishes on liquid insulin strips had delayed initiation of additional Phase III trials. Aradigm sees increased interest in its AERx pulmonary delivery system in the wake of Pfizer’s recent optimism about Exubera.
You may also be interested in...
Oralin Buccal Insulin May Face Easier Regulatory Path Than Inhaled Insulins, Generex Consultant Predicts
Oralin exposes only the oral cavity to insulin, Generex consultant Fleming says. Generex will pursue international approvals first with a more limited data package than FDA requires. Phase IIb trials have started in type 2 diabetes.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Wave’s Duchenne muscular dystrophy drug and Lilly’s chronic pain R&D will test the agency’s CID meeting pilot program, while FDA issues draft guidance that highlights potential uses for complex innovative trial designs.